LAG3 and neoplasm: Additionally, LSECtin expression in melanoma tumor cells and dendritic cells decreased the CD4 + and CD8 + T lymphocyte-mediated antitumor immune response through its interaction with LAG-3, clearly suggesting that LAG-3 inhibition may be triggered by multiple ligands that may be taken into consideration when developing therapies targeting this molecule (Fig. 2) [68].